

Ane Appelt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8518446/publications.pdf>

Version: 2024-02-01

53
papers

2,837
citations

304602

22
h-index

175177

52
g-index

53
all docs

53
docs citations

53
times ranked

3326
citing authors

#	ARTICLE	IF	CITATIONS
1	Dose summation and image registration strategies for radiobiologically and anatomically corrected dose accumulation in pelvic re-irradiation. <i>Acta Oncol</i> 2022, 61, 64-72.	0.8	11
2	GEC ESTRO ACROP consensus recommendations for contact brachytherapy for rectal cancer. <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 15-22.	0.9	12
3	Survival benefits for non-small cell lung cancer patients treated with adaptive radiotherapy. <i>Radiotherapy and Oncology</i> , 2022, 168, 234-240.	0.3	10
4	Deep Learning for Radiotherapy Outcome Prediction Using Dose Data – A Review. <i>Clinical Oncology</i> , 2022, 34, e87-e96.	0.6	19
5	A Phase II trial of Higher Radiotherapy Dose In The Eradication of early rectal cancer (APHRODITE): protocol for a multicentre, open-label randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e049119.	0.8	6
6	Prognostic factors for patients with anal cancer treated with conformal radiotherapy – a systematic review. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
7	The role of medical physicists in clinical trials across Europe. <i>Physica Medica</i> , 2022, 100, 31-38.	0.4	2
8	STAR-TREC phase II: Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer?. <i>Journal of Clinical Oncology</i> , 2022, 40, 3502-3502.	0.8	9
9	Dose-Response and Normal Tissue Complication Probabilities after Proton Therapy for Choroidal Melanoma. <i>Ophthalmology</i> , 2021, 128, 152-161.	2.5	12
10	Predicting outcomes in anal cancer patients using multi-centre data and distributed learning – A proof-of-concept study. <i>Radiotherapy and Oncology</i> , 2021, 159, 183-189.	0.3	18
11	A framework for voxel-based assessment of biological effect after proton radiotherapy in pediatric brain cancer patients using multi-modal imaging. <i>Medical Physics</i> , 2021, 48, 4110-4121.	1.6	11
12	Intensity modulated proton therapy planning study for organ at risk sparing in rectal cancer re-irradiation. <i>Acta Oncol</i> 2021, 60, 1436-1439.	0.8	4
13	International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 805-816.	12.5	93
14	3D image-guided treatment planning for Ruthenium-106 brachytherapy of choroidal melanomas. <i>Acta Ophthalmologica</i> , 2021, 99, e654-e660.	0.6	2
15	Long-Term Patient-Reported Outcomes After High-Dose Chemoradiation Therapy for Nonsurgical Management of Distal Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 556-563.	0.4	32
16	Image-Guided Radiotherapy for Pelvic Cancers: A Review of Current Evidence and Clinical Utilisation. <i>Clinical Oncology</i> , 2020, 32, 805-816.	0.6	25
17	In reply to letter to the editor: radiomic feature analysis of pre-treatment FDG PET-CT for predicting outcome in anal squamous cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2735-2736.	3.3	0
18	Tumour control probability after Ruthenium-106 brachytherapy for choroidal melanomas. <i>Acta Oncol</i> 2020, 59, 918-925.	0.8	9

#	ARTICLE	IF	CITATIONS
19	Prognostic Value of Serum NPY Hypermethylation in Neoadjuvant Chemoradiotherapy for Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 9-13.	0.6	15
20	Efficacy of Dose-Escalated Chemoradiation on Complete Tumor Response in Patients with Locally Advanced Rectal Cancer (RECTAL-BOOST): A Phase 2 Randomized Controlled Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1008-1018.	0.4	51
21	Mesorectal radiotherapy for early stage rectal cancer: A novel target volume. <i>Clinical and Translational Radiation Oncology</i> , 2020, 21, 104-111.	0.9	10
22	Outcome measures in multimodal rectal cancer trials. <i>Lancet Oncology</i> , The, 2020, 21, e252-e264.	5.1	56
23	Patient reported upper gastro-intestinal symptoms associated with fractionated image-guided conformal radiotherapy for metastatic spinal cord compression. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2020, 13, 1-5.	0.6	3
24	Predicting Visual Acuity Deterioration and Radiation-Induced Toxicities after Brachytherapy for Choroidal Melanomas. <i>Cancers</i> , 2019, 11, 1124.	1.7	20
25	Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2790-2799.	3.3	40
26	Robust dose planning objectives for mesorectal radiotherapy of early stage rectal cancer – A multicentre dose planning study. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2019, 11, 14-21.	0.6	12
27	Incorporating NTCP into Randomized Trials of Proton Versus Photon Therapy. <i>International Journal of Particle Therapy</i> , 2019, 5, 24-32.	0.9	2
28	Method for Automatic Selection of Parameters in Normal Tissue Complication Probability Modeling. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 704-712.	0.4	1
29	Phase 2 Neoadjuvant Treatment Intensification Trials in Rectal Cancer: A Systematic Review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 146-158.	0.4	13
30	Metal artefact reduction for accurate tumour delineation in radiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 479-486.	0.3	34
31	Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 825-836.	3.7	125
32	Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWDD): an international multicentre registry study. <i>Lancet</i> , The, 2018, 391, 2537-2545.	6.3	677
33	Ultrasonic mirror image from ruthenium plaque facilitates calculation of uveal melanoma treatment dose. <i>British Journal of Ophthalmology</i> , 2017, 101, 1206-1210.	2.1	3
34	Feasibility of preference-driven radiotherapy dose treatment planning to support shared decision making in anal cancer. <i>Acta Oncologica</i> , 2017, 56, 1277-1285.	0.8	4
35	The prognostic value of simultaneous tumor and serum <sc>RAS</sc>/<sc>RAF</sc> mutations in localized colon cancer. <i>Cancer Medicine</i> , 2017, 6, 928-936.	1.3	15
36	Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study. <i>Radiotherapy and Oncology</i> , 2017, 124, 311-317.	0.3	24

#	ARTICLE	IF	CITATIONS
37	Can we save the rectum by watchful waiting or transanal microsurgery following (chemo) radiotherapy versus total mesorectal excision for early rectal cancer (STAR-TREC study)? protocol for a multicentre, randomised feasibility study. <i>BMJ Open</i> , 2017, 7, e019474.	0.8	87
38	Technological advances in radiotherapy of rectal cancer: opportunities and challenges. <i>Current Opinion in Oncology</i> , 2016, 28, 353-358.	1.1	16
39	Late Relapses in Stage I Testicular Cancer Patients on Surveillance. <i>European Urology</i> , 2016, 70, 365-371.	0.9	34
40	Intratumoral Heterogeneity of MicroRNA Expression in Rectal Cancer. <i>PLoS ONE</i> , 2016, 11, e0156919.	1.1	16
41	High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. <i>Lancet Oncology</i> , The, 2015, 16, 919-927.	5.1	435
42	Radiation Techniques for Increasing Local Control in the Non-Surgical Management of Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 267-274.	1.0	2
43	Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer. <i>Acta Oncologica</i> , 2015, 54, 179-186.	0.8	25
44	Towards individualized dose constraints: Adjusting the QUANTEC radiation pneumonitis model for clinical risk factors. <i>Acta Oncologica</i> , 2014, 53, 605-612.	0.8	61
45	Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. <i>International Journal of Cancer</i> , 2014, 135, 2984-2991.	2.3	94
46	Long-Term Results of a Randomized Trial in Locally Advanced Rectal Cancer: No Benefit From Adding a Brachytherapy Boost. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 110-118.	0.4	46
47	Modern Hypofractionation Schedules for Tangential Whole Breast Irradiation Decrease the Fraction Size-corrected Dose to the Heart. <i>Clinical Oncology</i> , 2013, 25, 147-152.	0.6	57
48	KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2013, 109, 3067-3072.	2.9	48
49	Radiation Dose-Response Model for Locally Advanced Rectal Cancer After Preoperative Chemoradiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 74-80.	0.4	219
50	Improved heart, lung and target dose with deep inspiration breath hold in a large clinical series of breast cancer patients. <i>Radiotherapy and Oncology</i> , 2013, 106, 28-32.	0.3	196
51	Dose-Effect Relationship in Chemoradiotherapy for Locally Advanced Rectal Cancer: A Randomized Trial Comparing Two Radiation Doses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 949-954.	0.4	100
52	A method to adjust radiation dose-response relationships for clinical risk factors. <i>Radiotherapy and Oncology</i> , 2012, 102, 352-354.	0.3	9
53	The dose-effect relationship in preoperative chemoradiation of locally advanced rectal cancer: Preliminary results of a phase III trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, 3512-3512.	0.8	6